Overlapping of the spectra: Physical comorbidity between schizophrenia and affective disorders

The Overlap of Affective and Schizophrenic Spectra

Volumn 9780521858588, Issue , 2006, Pages 207-223

  Stone, William S ^a   Roe, Andrea H ^a   Tsuang, Ming T ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL SYMPTOMS; CO MORBIDITIES; CO-MORBID CONDITIONS; GLUCOSE REGULATION; MENTAL ILLNESS; MULTIPLE DIMENSIONS; PHYSICAL CONDITIONS; PHYSICAL DISORDERS;

DISEASES;

EID: 84928273725     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511544040.012     Document Type: Chapter

References (90)

1. Allison, D., Fontaine, K., Heo, M. et al. (1999). The distribution of body mass index among individuals with and without schizophrenia. Journal of Clinical Psychiatry, 60, 215–20.
2. Anderson, R., Freedland, K., Clouse, R. and Lustman, P. (2001). The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care, 24, 1069–78.
3. Apter, A., Laufer, N., Bar-Sever, M. et al. (1999). Serum cholesterol, suicidal tendencies, impulsivity, aggression, and depression in adolescent psychiatric inpatients. Biological Psychiatry, 46, 532–41.
4. Atmaca, M., Kuloglu, M., Tezcan, E., Ustundag, B. and Bayik, Y. (2002). Serum leptin and cholesterol levels in patients with bipolar disorder. Neuropsychobiology, 46, 176–9.
5. Baptista, T., Kin, N., Beaulieu, S. and de Baptista, E. A. (2001). Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives, Pharmacopsychiatry, 35, 207–19.
6. Basu, R., Brar, J. S., Chengappa, K. N. R. et al.(2004). The prevalence of the metabolic syndrome in patients with schizoaffective disorder – bipolar subtype. Bipolar Disorders, 6, 314–18.
7. Black, D. W. and Fisher, R. (1992). Mortality in DSM-IIIR schizophrenia. Schizophrenia Research, 7, 109–16.
8. Borgherini, G., Dorz, S., Conforti, D., Scarso, C. and Magni, G. (2002). Serum cholesterol and psychological distress in hospitalized depressed patients. Acta Psychiatrica Scandinavica, 105, 149–52.
9. Braceland, F. J., Meduna, L. J. and Vaichulis, J. A. (1945). Delayed action of insulin in schizophrenia. American Journal of Psychiatry, 102, 108–10.
10. Brown, S. (1997). Excess mortality of schizophrenia. A meta-analysis. British Journal of Psychiatry, 171, 502–8.
11. Brown, S., Inskip, H. and Barraclough, B. (2000). Causes of the excess mortality of schizophrenia. British Journal of Psychiatry, 177, 212–17.
12. Buka, S. L. and Fan, A. P. (1999). Association of prenatal and perinatal complications with subsequent bipolar disorder and schizophrenia. Schizophrenia Research, 39, 113–19.
13. Bushe, C. and Holt, R. (2004). Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia. British Journal of Psychiatry, 47(Suppl.), S67–71.
14. Cassidy, E., O’Halloran, D. and Barry, S. (1999). Insulin as a substance of misuse in a patient with insulin dependent diabetes mellitus. British Medical Journal, 319, 1417–18.
15. Chen, C., Lu, F., Wu, J. and Chang, C. (2001). Correlation between serum lipid concentrations and psychological distress. Psychiatry Research, 102, 153–62.
16. Cloninger, C. R., Kaufmann, C. A., Faraone, S. V. et al. (1998). Genome-wide search for schizophrenia susceptibility loci: The NIMH genetics initiative and millennium consortium. American Journal of Medical Genetics (Neuropsychiatric Genetics), 81, 275–81.
17. Convit, A., Wolf, O. T., Tarshish, C. and de Leon, M. J. (2003). Reduced glucose tolerance is associated with poor memory performance and hippocampal atrophy among normal elderly. Proceedings of the National Academy of Sciences of the United States of America, 100, 2019–22.
18. Davidson, M. (2002). Risk of cardiovascular disease and sudden death in schizophrenia. Journal of Clinical Psychiatry, 63 (Suppl. 9), 5–11.
19. Dixon, L., Weiden, P., Delahanty, J. et al. (2000). Diabetes and schizophrenia. Schizophrenia Bulletin, 26, 903–12.
20. Dwyer, D. S., Bradley, R. J., Kablinger, A. S. and Freeman, A. M., 3rd (2001). Glucose metabolism in relation to schizophrenia and antipsychotic drug treatment. Annals of Clinical Psychiatry, 13, 103–13.
21. Eaton, W., Armenian, H., Gallo, J., Pratt, L. and Ford, D. (1996). Depression and risk for onset of type II diabetes. A prospective population-based study. Diabetes Care, 19, 1097–102.
22. Elmslie, J. L., Silverstone, J. T., Mann, J. I., Williams, S. M. and Romans, S. E. (2000). Prevalence of overweight and obesity in bipolar patients. Journal of Clinical Psychiatry, 61, 179–84.
23. Ford, E. S. and Giles, W. H. (2003). A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care, 26, 575–81.
24. Ghaemi, S., Shields, G., Hegarty, J. and Goodwin, F. (2000). Cholesterol levels in mood disorders: high or low? Bipolar Disorders, 2, 60–4.
25. Gottesman, I. I. (2001). Award for Distinguished Scientific Contributions. American Psychologist, 56, 864–77.
26. Gunnell, D., Rasmussen, F., Fouskakis, D., Tynelius, P. and Harrison, G. (2003). Patterns of fetal and childhood growth and the development of schizophrenia and psychosis in young males: a cohort study. American Journal of Epidemiology, 158, 291–300.
27. Hagg, S., Joelsson, L., Mjorndal, T. et al. (1998). Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. Journal of Clinical Psychiatry, 59, 294–9.
28. Harris, E. and Barraclough, B. (1998). Excess mortality of mental disorder. British Journal of Psychiatry, 173, 11–53.
29. Heiskanen, T., Niskanen, L., Lyytikainen, R., Saarinen, P. I. and Hintikka, J. (2003). Metabolic syndrome in patients with schizophrenia. Journal of Clinical Psychiatry, 64, 575–9.
30. Henderson, R. A., Lane, S. and Henry, J. A. (1991). Life-threatening ventricular arrhythmia (torsades de pointes) after haloperidol overdose. Human Experimental Toxicology, 10, 59–62.
31. Holt, R. I. G., Pevelert, R. C. and Byrne, C. D. (2004). Schizophrenia, the metabolic syndrome and diabetes. Diabetic Medicine, 21, 515–23.
32. Horrobin, D. F. and Bennett, C. N. (1999). Depression and bipolar disorder: Relationships to impaired fatty acid and phospholipid metabolism and to diabetes, cardiovascular disease, immunological abnormalities, cancer, ageing and osteoporosis: Possible candidate genes. Prostaglandins, Leukotrienes and Essential Fatty Acids, 60, 217–34.
33. Jeste, D. V., Gladsjo, J. A., Lindamer, L. A. and Lacro, J. P. (1996). Medical comorbidity in schizophrenia. Schizophrenia Bulletin, 22, 413–27.
34. Kaiya, H. (1991). Prostaglandin E1 suppression of platelet aggregation response in schizophrenia. Schizophrenia Research, 5, 67–80.
35. Kilbourne, A., Cornelius, J., Han, X. et al. (2004). Burden of general medical conditions among individuals with bipolar disorder. Bipolar Disorders, 6, 368–73.
36. Klumpers, U. M. H., Boom, K., Janssen, F. M. G., Tulen, J. H. M. and Loonen, A. J. M. (2004). Cardiovascular risk factors in outpatientswith bipolar disorder. Pharmacopsychiatry, 37, 211–16.
37. Kooy, F. (1919). Hyperglycaemia in mental disorders. Brain, 42, 214–88.
38. Koran, L. M., Sox, H. C., Marton, K. I. et al. (1989). Medical evaluation of psychiatric patients. I. Result in a state mental health system. Archives of General Psychiatry, 46, 733–40.
39. Lakka, H.-M., Laaksonen, D. E., Lakka, T. A. et al. (2002). The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. Journal of the American Medical Association, 288, 2709–16.
40. Ledochowski, M., Murr, C., Sperner-Unterweger, B., Neurauter, G. and Fuchs, D. (2003). Association between increased serum cholesterol and signs of depressive mood. Clinical Chemistry and Laboratory Medicine, 41, 821–4.
41. Levin, B. E. (2000). Glucose-regulated dopamine release from substantia nigra neurons. Brain Research, 874, 158–64.
42. Lilliker, S. (1980). Prevalence of diabetes in a manic-depressive population. Comprehensive Psychiatry, 21, 270–5.
43. Lindenmayer, J.-P. and Patel, R. (1999). Olanzapine-induced ketoacidosis with diabetes mellitus. American Journal of Psychiatry, 156, 1471.
44. Littrell, K., Petty, R., Hilligoss, N. et al. (2003). Insulin resistance and syndrome X among schizophrenic patients. In Meeting of the American Psychiatry Association. San Francisco, California.
45. Lovett Doust, J. W. (1980). Sinus tachycardia and abnormal cardiac rate variation in schizophrenia. Neuropsychobiology, 6, 305–12.
46. Lozovsky, D. B., Kopin, I. J. and Saller, C. F. (1985). Modulation of dopamine receptor supersensitivity by chronic insulin: implication in schizophrenia. Brain Research, 343, 190–3.
47. Lozovsky, D. B., Saller, C. F. and Kopin, I. J. (1981). Dopamine receptor binding is increased in diabetic rats. Science, 214, 1031–3.
48. Maes, M., Smith, R., Christophe, A. et al. (1997). Lower serum high-density lipoprotein cholesterol (HDL-C) in major depression and in depressed men with serious suicidal attempts: relationship with immune-inflammatory markers. Acta Pscyhiatrica Scandinavica, 95, 212–21.
49. Marder, S. R., Essock, S. M., Miller, A. L. et al.(2004). Physical health monitoring of patients with schizophrenia. American Journal of Psychiatry, 161, 1334–49.
50. Maudsley, H. (1879) The Pathology of Mind. London: Macmillan.
51. McCallum, J., Simons, L., Simons, J. and Friedlander, Y. (1994). Low serum cholesterol is not associated with depression in the elderly: data from an Australian community study. Australian and New Zealand Journal of Medicine, 24, 561–4.
52. McElroy, S. L., Kotwal, R., Malhotra, S. et al. (2004). Are mood disorders and obesity related? A review for the mental health professional. Journal of Clinical Psychiatry, 65, 634–51.
53. Moldin, S., Scheftner, W., Rice, J. et al. (1993). Association between major depressive disorder and physical illness. Psychological Medicine, 23, 755–61.
54. Morgan, R., Palinkas, L., Barrett-Connor, E. and Wingard, D. (1993). Plasma cholesterol and depressive symptoms in older men. Lancet, 341, 75–9.
55. Mukherjee, S., Decina, P., Bocola, V., Saraceni, F. and Scapicchio, P. (1996). Diabetes mellitus in schizophrenic patients. Comprehensive Psychiatry, 37, 68–73.
56. Mukherjee, S., Schnur, D. B. and Reddy, R. (1989). Family history of type 2 diabetes in schizophrenic patients. Lancet, 1, 495.
57. Newcomer, J. W., Craft, S., Fucetola, R. et al. (1999). Glucose-induced increase in memory performance in patients with schizophrenia. Schizophrenia Bulletin, 25, 321–35.
58. Newcomer, J. W., Haupt, D. W., Fucetola, R. et al. (2002). Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Archives of General Psychiatry, 59, 337–45.
59. Newman, S. C. and Bland, R. C. (1991). Mortality in a cohort of patients with schizophrenia: a record linkage study. Canadian Journal of Psychiatry, 36, 239–45.
60. Newsome, C. A., Shiell, A. W., Fall, C. H. et al. (2003). Is birth weight related to later glucose and insulin metabolism? A systematic review. Diabetic Medicine, 20, 339–48.
61. Olusi, S. and Fido, A. (1996). Serum lipid concentrations in patients with major depressive disorder. Biological Psychiatry, 40, 1128–31.
62. Osby, U., Brandt, L., Correia, N., Ekbom, A. and Sparen, P. (2001). Excess mortality in bipolar and unipolar disorder in Sweden. Archives of General Psychiatry, 58, 844–50.
63. Partonen, T., Haukka, J., Virtamo, J., Taylor, P. and Lonnqvist, J. (1999). Association of low serum total cholesterol with major depression and suicide. British Journal of Psychiatry, 175, 259–62.
64. Philips, R. J. (1934). Physical disorder in 164 consecutive admissions to a mental hospital: the incidence and significance. British Medical Journal, 2, 363–6.
65. Popli, A. P., Konicki, P. E., Jurjus, G. J., Fuller, M. A. and Jaskiw, G. E. (1997). Clozapine and associated diabetes mellitus. Journal of Clinical Psychiatry, 58, 108–11.
66. Reaven, G. (1988). Role of insulin resistance in human disease. Diabetes, 37, 1595–607.
67. Reaven, G. (2004). The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinology and Metabolism Clinics of North America, 33, 283–303.
68. Regenold, W., Thapar, R., Marano, C., Gavirneni, S. and Kondapavuluru, P. (2002). Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. Journal of Affective Disorders, 70, 19–26.
69. Rosmond, R. (2005). Role of stress in the pathogenesis of the metabolic syndrome. Psychoneuroendocrinology, 30, 1–10.
70. Rugulies, R. (2003). Depression as a predictor for coronary heart disease. A review and metaanalysis. American Journal of Preventive Medicine, 23, 51–61.
71. Ryan, M. C. M., Collins, P. and Thakore, J. H. (2003). Impaired fasting glucose tolerance in firstepisode, drug-naive patients with schizophrenia. American Journal of Psychiatry, 160, 284–9.
72. Ryan, M. C. M. and Thakore, J. H. (2002). Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sciences, 71, 239–57.
73. Saari, K., Jokelainen, J., Veijola, J. et al. (2004). Serum lipids in schizophrenia and other functional psychoses: a general population northern Finland 1966 birth cohort survey. Acta Psychiatrica Scandinavica, 110, 279–85.
74. Sacks, F. M. (2004). Metabolic syndrome: epidemiology and consequences. Journal of Clinical Psychiatry, 65(Suppl. 18), 3–12.
75. Saller, C. F. and Chiodo, L. A. (1980). Glucose suppresses basal firing and haloperidol-induced increases in the firing rate of central dopaminergic neurons. Science, 210, 1269–71.
76. Schimmelbusch, W., Mueller, P. and Sheps, J. (1971). The positive correlation between insulin resistance and duration of hospitalization in untreated schizophrenia British Journal of Psychiatry, 118, 429–36.
77. Seidman, L. J., Kremen, W. S., Koren, D. et al. (2002). A comparative profile analysis of neuropsychological functioning in patients with schizophrenia and bipolar psychoses. Schizophrenia Research, 53, 31–44.
78. Stone, W. S., Faraone, S. V., Su, J. et al. (2004a). Evidence for linkage between regulatory enzymes in glycolysis and schizophrenia in a multiple sample. American Journal of Medical Genetics – Part B: Neuropsychiatric Genetics, 127B, 5–10.
79. Stone, W. S., Glatt, S. J. and Faraone, S. V. (2004b). The biology of schizotaxia. In Early Clinical Intervention and Prevention of Schizophrenia, eds. W. S. Stone, S. V. Faraone and M. T. Tsuang. Totowa, New Jersey: Humana Press, pp. 339–53.
80. Stone, W. S., Seidman, L. J., Wojcik, J. D. and Green, A. I. (2003). Glucose effects on cognition in schizophrenia. Schizophrenia Research, 62, 93–103.
81. Stone, W. S., Thermenos, H. W., Tarbox, S. I., Poldrack, R. A. and Seidman, L. J. (2005). Medial temporal and prefrontal lobe activation during verbal encoding following glucose ingestion in schizophrenia: A pilot fMRI study. Neurobiology of Learning and Memory, 83, 54–64.
82. Stone, W. S., Wenk, G. L., Olton, D. S. and Gold, P. E. (1990). Poor blood-glucose regulation predicts sleep and memory deficits in normal aged rats. Journal of Gerontology: Biological Sciences, 45, B169–173.
83. Subramaniam, M., Chong, S. A. and Pek, E. (2003). Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia. Canadian Journal of Psychiatry, 48, 345–7.
84. Thakore, J. (2004). Metabolic disturbance in first-episode schizophrenia. British Journal of Psychiatry, 47(Suppl.), S76–9.
85. Thakore, J. H., Mann, J. N., Vlahoos, J., Martin, A. and Reznek, R. (2002). Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. International Journal of Obesity Related Metabolic Disorders, 26, 137–41.
86. Thakore, J. H., Richards, P. J., Reznek, R. H., Martin, A. and Dinan, T. G. (1997). Increased intraabdominal fat deposition in patients with major depressive illness as measured by computed tomography. Biological Psychiatry, 41, 1140–2.
87. Walker, J., Curtis, V. and Murray, R. M. (2002). Schizophrenia and bipolar disorder: similarities in pathogenic mechanisms but differences in neurodevelopment. International Clinical Psychopharmacology, 17(Suppl. 3), S11–19.
88. Weber-Hamann, B., Hentschel, F., Kniest, A. et al. (2002). Hypercortisolemic depression is associated with increased intra-abdominal fat. Psychosomatic Medicine, 64, 274–7.
89. Wright, P., Sham, P. C., Gilvarry, C. M. et al. (1996). Autoimmune diseases in the pedigrees of schizophrenic and control subjects. Schizophrenia Research, 20, 261–7.
90. Wulsin, L. R. and Singal, B. M. (2003). Do depressive symptoms increase the risk for the onset of coronary disease? A systematic quantitative review. Psychosomatic Medicine, 65, 201–10.